No-Stoma Policy in Advanced Ovarian Cancer Surgery
ConditionOvary Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
About this trial
Resection of the sigmoid-rectum is a procedure frequently required in cytoreductive surgery for advanced ovarian cancer, and it is also among the procedures with the highest risk of complications. One of the major, albeit uncommon, complications of intestinal anastomosis is anastomotic leakage. According to the literature, the rate of anastomotic leakage following cytoreductive surgery for ovarian cancer ranges from 1.7% to 17%.
The risk factors associated with this complication are varied and often inconsistent across studies. They range from preoperative clinical conditions-such as age, low albumin levels, and Body Mass Index \< 18-to intraoperative factors such as low to mid rectal resection, high ligation of the inferior mesenteric artery, and multiple bowel resections.
Apart from the rehabilitative programs introduced by the Enhanced Recovery After Surgery protocol-which aim to improve the nutritional status of patients undergoing cytoreductive surgery for ovarian cancer-we currently lack validated tools to reduce the risk of leakage. The most commonly used strategy remains the creation of a protective stoma. However, several studies have shown that this procedure is not actually a protective factor against anastomotic leakage; rather, its utility lies in mitigating the severity of the complication.
Nonetheless, stomas have a significant clinical and psychological impact, with complication rates ranging from 33.9% to 45% and reversal rates between 66.5% and 89%.
This study aims to evaluate the feasibility of a no-stoma strategy in a selected "low-risk" population for anastomotic leakage among patients undergoing cytoreductive surgery for primary or recurrent ovarian cancer. Focusing on the goal of achieving a zero stoma rate, the study will provide valuable insights into the utility and outcomes of stoma creation. The results will support more informed and patient-centered clinical decisions in the management of ovarian cancer.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with suspected or anatomopathological diagnosis of malignant ovarian tumor undergoing elective primary or secondary cytoreduction and needing rectosigmoid resection and anastomosis
Informed consent signed prior to performing any procedure related to the clinical trial
Age 18 years old.
Disqualifiers
Patients with histologies other than ovarian tumor.
Only palliative surgery planned
Patients who do not require sigmoid-rectum resection after intraoperative evaluation
Patients who do not receive colorectal anastomosis and undergo end ostomy
Trial design
Design model
Single group
Treatments tested in this trial
colon-rectal resection
Procedure/SurgeryThe patients who underwent colon rectal resection, would be evaluated for stomia or not.
Treatment groups
395 Participants
are divided into 1 treatment groupGroup A: Women with ovarian cancerExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Rate of Anastomotic Dehiscence in Low-Risk Patients Undergoing Primary or Secondary Cytoreductive Surgery for Ovarian, Fallopian Tube, or Peritoneal Tumors
The feasibility of a no-stoma policy will be assessed by calculating the rate of anastomotic dehiscence in low-risk patients (who therefore did not receive a diverting stoma) and comparing these results with published data from the literature.
Time frame
Intraoperative and postoperative follow-up period (90 days postoperative)Secondary outcomes
1
Risk Factors for Anastomotic Leak
Identification of preoperative and intraoperative variables associated with anastomotic leak using a multivariable logistic regression model.
Time frame
preoperative, intraoperative2
Rate of Occult Anastomotic Leak in Patients With Diverting Ostomy
Proportion of asymptomatic patients with diverting ostomy presenting with occult anastomotic leak, as assessed by water-soluble rectal contrast enema performed between postoperative days 5 and 10.
Time frame
Postoperative days up to 20.3
Management Strategies for Anastomotic Leak
Description and distribution of management strategies for anastomotic leak (conservative vs. non-conservative), stratified by low- and high-risk patient groups, and evaluation of the role of ostomy in leak management.
Time frame
Postoperative period (up to 90 days).4
Impact of Bowel Surgery on Quality of Life
Change in quality of life and bowel function, as measured by: Gastrointestinal Quality of Life Index (GIQLI) in all patients STOMA questionnaire in patients with diverting ostomy Low Anterior Resection Syndrome (LARS) score Knowles-Eccersley-Scott-Symptom (KESS) questionnaire All questionnaires will be administered preoperatively and at 3 and 6 months post-surgery.
Time frame
Baseline (pre-surgery), 3 months, and 6 months post-surgery.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov